Management of Constipation in Patients with Pancreatic Stents

Treatment Approach

The American Gastroenterological Association recommends starting with polyethylene glycol (PEG) as the preferred osmotic laxative for chronic constipation in patients with pancreatic stents, due to its superior efficacy and tolerability, with a strong recommendation and moderate certainty of evidence 1, 2
If PEG fails or is not tolerated, lactulose becomes a reasonable second-line option, with a conditional recommendation reflecting very low certainty of evidence, but decades of clinical experience supporting its safety profile 1, 2

The American Gastroenterological Association suggests beginning with 10-20 g (15-30 mL) of lactulose once daily in the evening, which can be titrated up to 40 g (60 mL) daily if needed, to minimize dose-dependent gastrointestinal side effects 3
Lactulose has no specific contraindications in patients with pancreatic stents, as its mechanism of action does not interfere with pancreatic stent function, according to the American Gastroenterological Association 1, 3

Patients on lactulose should be monitored for common side effects such as bloating, flatulence, and abdominal pain, which can occur in approximately 20% of patients, and may complicate the clinical picture 1, 3
Excessive dosing of lactulose can lead to diarrhea with potential electrolyte disturbances, including hypokalemia and hypernatremia, highlighting the need for careful dose titration 3

Bisacodyl 10-15 mg daily can be used short-term (≤4 weeks) or as rescue therapy if osmotic laxatives are insufficient, according to the National Comprehensive Cancer Network 4, 2
Magnesium oxide 500 mg to 1.5 g daily is another osmotic option, but should be avoided in patients with renal insufficiency (creatinine clearance <20 mg/dL), as recommended by the American Gastroenterological Association 1, 2